Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis

Gilbert, Morgan; Scherrer, Leigh Ann

doi:10.1111/dth.12758

Cited by 34 publications

(38 citation statements)

References 16 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, for all patients, the treatment with the suspected drug was terminated at the first sign of symptoms of SCARs. There have beenmany published reports suggesting the benefit of certain anti-inflammatory drugs [34][35][36][37]. A total of 64 patients (91.4%) in our study received systemic corticosteroids, which is consistent previous reports [22,24].…”

supporting

confidence: 91%

Severe Cutaneous Adverse Reactions to Drugs in Latin America: The RACGRAD Study

Mejía¹,

Zwiener²,

Villa³

et al. 2021

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

supporting

confidence: 91%

Severe Cutaneous Adverse Reactions to Drugs in Latin America: The RACGRAD Study

Mejía¹,

Zwiener²,

Villa³

et al. 2021

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

“…Toxic epidermal necrolysis and Stevens-Johnson syndrome are acute inflammatory skin reactions [ 1 ]. SJS/TEN can affect any age group but is more prevalent in women, patients with HIV, and elderly.…”

Section: Introductionmentioning

confidence: 99%

“…Toxic epidermal necrolysis is associated with 30%–50% mortality and long-term sequelae [ 3 ]. Treatment involves early cessation of causative medication, supportive care, and admission to burn unit if needed [ 1 ]. Specific treatment with immunosuppressive drugs or immunoglobulins showed conflicting results regarding outcomes, and it remains controversial [ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…Treatment involves early cessation of causative medication, supportive care, and admission to burn unit if needed [ 1 ]. Specific treatment with immunosuppressive drugs or immunoglobulins showed conflicting results regarding outcomes, and it remains controversial [ 1 , 2 ]. The disease mechanism is not fully understood, but it appears that there are immunological mechanisms, cytotoxic reactions, and delayed hypersensitivity that could be involved in the pathogenesis [ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Toxic Epidermal Necrolysis (TEN)/Stevens-Johnson Syndrome (SJS) Epidemiology and Mortality Rate at King Fahad Specialist Hospital (KFSH) in Qassim Region of Saudi Arabia: A Retrospective Study

Alajaji

Shekaran

AlDhabbah

et al. 2020

Dermatology Research and Practice

View full text Add to dashboard Cite

Background. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are life-threatening conditions caused by drug reactions. There are multiple causative drugs and different risk factors associated with SJS/TEN. Objectives. To study the epidemiology of SJS/TEN and associated mortality rate in Qassim region, Saudi Arabia. Methodology. A retrospective chart review of all patients with the diagnosis of SJS/TEN who were admitted to King Fahad Specialist Hospital (KFSH) in Qassim region, Saudi Arabia, for the period between Jan 2014 to Jan 2019. The Careware information health system is used at KFSH, and patients were identified searching the diagnosis SJS/TEN. Results. Total of 10 patients with diagnosis of SJS/TEN were admitted to KFSH for the period from Jan 2014 to Jan 2019. Antibiotics were the culprit in 5 out of 10 patients. 9 out of 10 patients survived with good outcome. One patient with the diagnosis of TEN died, given extensive skin involvement complicated by sepsis. Conclusion. Despite the limitation of this study given small sample size, this is the first study of its kind that discusses the epidemiology of SJS/TEN in Saudi Arabia. We found the estimated incidence rate of SJS/TEN in Qassim region to be 7.6 cases per million person-years. Antibiotics and antiepileptics were the culprits in 8 out of 10 patients.

show abstract

“…3 Evidence-based treatment guidelines are lacking. Extrapolating from the SJS literature, 4 we have used cyclosporine A (CsA) to reduce the duration and morbidity of MIRM and we report our experience here.…”

Section: Introductionmentioning

confidence: 99%

Treatment ofMycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine

Colantonio

Ramien

2019

J Cutan Med Surg

View full text Add to dashboard Cite

Background Mycoplasma pneumoniae-induced rash and mucositis (MIRM) is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin . Objective This case series aims to describe the potential efficacy of cyclosporine A (CsA) in the treatment of MIRM. Methods The present case series details our use of CsA early in the course of MIRM in 3 pediatric patients. Results Rapid clinical resolution was observed following CsA therapy. Conclusions We suggest that early initiation of CsA may be an effective therapeutic option for MIRM.

show abstract

Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis

Cited by 34 publications

References 16 publications

Severe Cutaneous Adverse Reactions to Drugs in Latin America: The RACGRAD Study

Severe Cutaneous Adverse Reactions to Drugs in Latin America: The RACGRAD Study

Toxic Epidermal Necrolysis (TEN)/Stevens-Johnson Syndrome (SJS) Epidemiology and Mortality Rate at King Fahad Specialist Hospital (KFSH) in Qassim Region of Saudi Arabia: A Retrospective Study

Treatment ofMycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine

Contact Info

Product

Resources

About